An Observational, Prospective, Safety Study of Mircera (Monopegylated Epoetin Beta) in Clinical Practice

Hoffmann-La Roche748 enrolled

Overview

This national study was a post-marketing surveillance study conducted in Korea from 29 August 2008 to 28 August 2012 to meet local regulatory requirements for Mircera (monopegylated-epoetin beta). Prospective participant-based data collection was evaluated for safety/risk assessments and effectiveness. No specific study-related procedures are required. Participants were to be followed up as long as possible at the physician's discretion.

Study Type

OBSERVATIONAL

Enrollment

748

Conditions

Kidney Disease, Chronic

Interventions

MirceraDRUG

Participants received Mircera according to individualized physician-prescribed regimen.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult, aged \>18 years * Participants with stage 3-5 chronic kidney disease and hemodialyzed participants * Signed informed consent Exclusion Criteria: * Current participation in a clinical study

Locations (1)

Unnamed facility

Seoul, South Korea

Outcomes

Primary Outcomes

Percentage of Participants With an Adverse Event (AE) and a Serious Adverse Event

An AE was defined as any untoward medical occurrence in a participant administered with Mircera and which does not necessarily have a causal relationship with Mircera. A Serious Adverse Event (SAE) is any experience that suggests a significant hazard, contraindication, side effect or precaution. It is any AE that at any dose fulfills at least one of the following criteria: is fatal; is life threatening; requires in-patient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is medically significant or requires intervention to prevent one or other of the outcomes listed above.

Time frame: At physician's discretion, up to 4 years

Percentage of Participants With an Adverse Drug Reaction (ADR)

ADRs were defined as any response to a drug which was noxious and unintended, and which occurred at dose normally used related to the pharmacological properties. It was defined as any AE categorized as "definitely related","probably related", "possibly related", and "unknown" by investigators. In case that an ADR was not written on local Korean Mircera label, it was classified as "Unexpected". An AE was defined as any untoward medical occurrence in a participant administered with Mircera and which does not necessarily have a causal relationship with Mircera.

Time frame: At physician's discretion, up to 4 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.